lncRNA *NORM* is essential for proper chromosome segregation through the Plk1-Bub1 and Nsun2 axis.

Vikas Dongardive[1], Sonali Jathar[1], Juhi Srivastava[1] and Vidisha Tripathi[1*]

[1]Laboratory of lncRNA Biology, National Centre for Cell Science, NCCS Complex, Savitribai Phule Pune University Road, Pune-411007, MH, INDIA

*Address correspondence to: Vidisha Tripathi (tvidisha@nccs.res.in)

Running Title: NORM coordinate Plk1-Bub1-Nsun2 in chromosome segregation

Abbreviations: BrdU-5-bromo-2'-deoxyuridine ; CDK-Cyclin Dependent Kinase ; CPAT-Coding Potential Assessment Tool ,CPC-Coding Potential Calculator ; FACS-Fluorescence-activated single cell sorting ; KT-Kinetochore; LNA-ASO -Locked nucleic acid- anti sense oligonucleotide; lncRNA-Long noncoding RNA ;MT-Microtubule; Nsun2-NOP2/Sun RNA methyltransferase 2; Plk1-Polo-like kinase 1; RIP-RNA immunoprecipitation ; SAC -Spindle assembly checkpoint ;SCR-Scramble

Abstract:

The cell cycle comprises different phases and is a tightly regulated process at the molecular
level. During the cell cycle, two key events occurred: DNA duplication during the S phase and
chromosome segregation during mitosis. Accurate cell cycle progression, achieved through
faithful chromosome segregation, is essential for maintaining cell fidelity. Long noncoding
RNAs are a subclass of noncoding RNA that are longer than 200 bp and form RNA protein
complexes (RNPs) to regulate various biological processes. Herein, we demonstrate that
lncRNA *NORM* is involved in regulating the cell cycle by maintaining proper chromosome
segregation. *NORM* exhibited G2 phase-specific expression, and the depletion of *NORM*
resulted in a significant G2/M arrest. *NORM*-depleted cells failed to progress in mitosis and
showed defects in chromosome segregation. We further demonstrated that *NORM* binds to
proteins such as Plk1 and Nsun2. Depletion of *NORM* hindered the interaction between Plk1
and Bub1, resulting in reduced kinetochore localization of Plk1 during prometaphase. Our
results also show that the depletion of *NORM* affects the binding of Nsun2 protein to CDK1
mRNA and, consequently, the stabilization of CDK1 at the protein level. Altogether, our results
demonstrate that *NORM* regulates chromosome segregation by mediating the interaction
between Plk1 and Bub1.

Keywords: long noncoding RNA, cell cycle, chromosome segregation, Plk1, Bub1,
Mitosis.

Introduction:

The mammalian cell cycle is a ubiquitous and tightly regulated process that comprises events orchestrated in an orderly manner to culminate in the formation of two daughter cells. The entry of a cell into different phases of the cell cycle is precisely controlled by the oscillating concentrations of different Cyclins and CDK complexes. In addition to Cyclins and CDKs, various cyclin kinase inhibitors (CKIs) and cell cycle regulatory proteins, such as RB, p53, and p21, regulate the cell cycle (1,2). Two key events that occur during the cell cycle are the duplication of genetic material in the S phase and the segregation of chromosomes in the M phase. Precise control of chromosome segregation during the M phase is crucial for error-free cell cycle progression, as any defect in chromosome segregation can lead to cellular abnormalities that ultimately contribute to the development of various cellular disorders, including cancer (3). One of the key events that is responsible for faithful chromosome segregation is the attachment of the kinetochore to microtubules (KT-MT) (4). A plethora of proteins are involved in mediating the proper attachment of KT-MT for the segregation of chromosomes. Any defect in chromosome segregation is detected by the surveillance mechanism known as the spindle assembly checkpoint (SAC), which is activated to correct the erroneous microtubule-to-kinetochore attachment (5). Budding uninhibited by benzimidazoles 1 (Bub1) plays a pivotal role in assembling the SAC complex by localizing at the kinetochore through the phosphorylation of Knl1 by Mps (6,7). Phosphorylated Knl1 then recruits the Bub3-Bub1 complex. Additionally, Mps1 phosphorylates Bub1 to mediate its interaction with the Mad1-Mad2 complex, thereby creating a SAC signaling platform (8). This platform then further recruits Bub3, BubR1, Cdc20, and Mad2. Bub1 also binds to another kinase, Polo-like kinase 1 (Plk1), and the interaction between Plk1 and Bub1 is essential for the kinetochore localization of Plk1. Any defects in Plk1 kinetochore localization cause chromosome mis-segregation, marked by chromosomes associated with spindle poles (9). The interaction between Bub1 and Plk1 primarily depends on Bub1's phosphorylation at T609, mediated by the CDK1 protein (9). The Cyclin B and CDK1 complex drives the entry of a cell into mitosis and is crucial for guaranteeing accurate and faithful segregation of duplicated chromosomes. CDK1 is also regulated by various proteins, such as MYT1 and WEE1, which deactivate CDK1 through phosphorylation (10,11). Moreover, CDK1 is also regulated through mRNA stabilization by the protein binding to its mRNA. NOP2/Sun RNA methyltransferase family, member 2 (NSun2) (Misu) stabilizes CDK1 and enhances its translation by binding to its mRNA and methylating its 3' untranslated region (UTR) (12). CDK1 binds to Cyclin B and becomes activated. Upon activation, it phosphorylates various substrates, including Bub1, which is crucial for mitosis and contributes to the faithful segregation of chromosomes. Multiple lines of evidence suggest that noncoding RNAs, including microRNAs (miRNAs) and long

noncoding RNAs (lncRNAs), are also involved in regulating the cell cycle. lncRNAs are a class

of noncoding RNAs that are longer than 200 bp and characterized by their short open reading

frame. By forming RNP complexes, lncRNAs are known to control a variety of biological

processes through Signal, decoy, Guide, or Scaffold mechanisms. In a recent study, it has

been demonstrated that lncRNA MALAT1 is differentially regulated during the G1/S and M

phases and is essential for the progression of the cell cycle from G1/S to S and from G2 to M,

through the transcription and alternative splicing of the gene bMyb (13). Another study has

demonstrated that the lncRNA EMS controls the cell cycle progression during the G1/S phase.

EMS stabilizes E2F1 mRNA by binding to the RALLY protein in a manner that increases the

expression of that gene (14). lncRNAs also interact with CDKs to regulate cell cycle

progression. A recent study revealed that lncRNA HOXC-AS3 interacts with CDK2, thereby

facilitating reduced binding of CDK2 to p21, which ultimately leads to increased CDK2 activity

and promotes cell proliferation (15). Several other studies have demonstrated that many long

noncoding RNAs (lncRNAs) play a role in cell cycle regulation. Among these lncRNAs,

LINC00667 is an interesting lncRNA due to its recently studied role in multiple diseases,

specifically in cancers and chronic kidney diseases. Recently, various studies have shown

that LINC00667 is differentially expressed in various cancer cell lines and plays a crucial role

in regulating cellular proliferation, invasion, migration, and apoptosis (16–19).Overexpression

of LINC00667 in renal tubular epithelial cells results in chronic renal fibrosis by increasing

cellular proliferation, migration, and apoptosis through the miR-19b-3p/LINC00667/CTGF

axis(16). Upregulation of LINC00667 in clear renal carcinoma is associated with increased

cellular proliferation, migration, and invasion, achieved through the targeting of miR-143-3p

and a subsequent increase in ZEB1 expression (20). Furthermore, LINC00667 also plays an

oncogenic role in various cancers, including Wilms' tumor, through the miR-200b/c/429 and

IKK-β axis (18). In non-small cell lung cancer, it plays its role via EIF4A3-stabilized

VEGFA(17). In breast cancer, LINC00667 drives tumor growth and chemoresistance to

docetaxel through the miR-200/Bcl2 axis (21). Additional evidence suggests that LINC006677

is upregulated in nasopharyngeal carcinoma, enhancing proliferation, migration, and the

epithelial-to-mesenchymal transition by sponging miR-4319 and regulating the level of FOXQ1

(22). In esophageal cancer, LINC00667 is associated with promoting proliferation through the

LINC00667/miR-200b-3p/SLC2A3 axis(23). In cholangiocarcinoma, LINC00667 regulates

tumor growth through YY1-mediated upregulation (24). Together, these findings highlight

LINC00667 as a crucial molecular regulator of proliferation in cancer and kidney disease,

underscoring the need for further investigation to elucidate its mechanisms and therapeutic

potential. Its consistent involvement in regulating cellular proliferation hints at a broader role

in cell cycle control, an area that remains largely unexplored. Understanding this potential

connection may uncover new therapeutic avenues for diseases where aberrant cell cycle

regulation is a hallmark. Understanding the involvement of lncRNAs in cell cycle regulation
will provide a detailed molecular mechanism and open up new opportunities for novel
treatments of cellular disorders associated with cell cycle dysregulation.

In this study, we showed the involvement of LINC00667 in regulating the cell cycle. We
demonstrated that long noncoding RNA LINC00667 is crucial for proper chromosomal
segregation by modulating the interaction between Plk1 and Bub1. LINC00667 is a G2-phase
enriched lncRNA and is essential for driving the G2/M progression of the cell. LINC00667
depletion causes G2/M arrest of cells marked with chromosome misalignment, which
ultimately results in cell apoptosis. The interaction between Plk1 and Bub1 is hampered upon
LINC00667 depletion. We have demonstrated the molecular relationship between LINC00667
and another protein, Nsun2. Additionally, we have demonstrated that LINC00667 depletion
reduces the binding of Nsun2 to CDK1 mRNA, thereby decreasing the stability of the CDK1
protein. We observed that a reduced level of CDK1 protein results in a decrease in the
phosphorylation of Bub1 at T609. Finally, Plk1 localization at the kinetochore is altered as a
result of hindering the interaction between Plk1 and Bub1. Overall, our research suggests that
the novel long non-coding RNA (lncRNA) LINC00667 plays a crucial role in regulating the cell
cycle by ensuring normal chromosome segregation.

Results:

***NORM* is upregulated during the G2 phase of the cell cycle and promotes G2/M**
transition

Tumour cells adapt pathways that bypass normal cell cycle checkpoints to enable unregulated
cell division. Uncontrolled proliferation is often driven by signalling pathways that alter the
expression of cell cycle regulators such as cyclins, cyclin-dependent kinases (CDKs), and
CDK inhibitors. Therefore, oncogenic lncRNAs such as LINC00667, which promote
proliferation, may exert their function at least in part by regulating cell cycle processes. Recent
studies have demonstrated that one such long non-coding RNA (lncRNA), LINC00667, is
differentially regulated in various cancers and plays a role in regulating proliferation.
Uncontrolled cellular proliferation is one of the hallmarks of cancer, often resulting from defects
in the cell cycle regulation program. The cell cycle is a more complex phenomenon that is
coordinated through multiple layers of regulation, driven by proteins as well as a wide array of
noncoding RNAs, including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs). One
of our comprehensive studies has identified a set of cell cycle-related long noncoding RNAs
(lncRNAs), with most of these lncRNAs exhibiting cell cycle phase-specific expression
patterns. LINC00667 is one such lncRNA that showed G2 phase-specific expression in

synchronized HeLa cells. Based on its function, we named LINC00667 the Noncoding RNA

Regulator of Mitosis *(NORM)*. *NORM* is approx. 4.0 nucleotides long noncoding transcript

located on chromosome 18 (chr18:5,232,875-5,290,608 (GRCh38/hg38)), Histone tail

modification map indicated a significant H3K4me3 and H3K27ac marks on the promoter of

NORM, indicating that it is actively transcribed across different cell types **[FIG 1A].** The coding

probability of the *NORM* transcript was analyzed using the CPAT tool, revealing that *NORM*

does not code for any protein, unlike the well-characterized long noncoding RNA MALAT1

[FIG. 1B]. To understand its cis-acting or trans-acting mode, *NORM* was further characterized

for its subcellular localization using a subcellular fractionation method, followed by a

quantitative real-time PCR analysis to assess the level of *NORM*. Quantitative real-time PCR

data revealed that *NORM* is predominantly located in the nucleus, with some fraction also

present in the cytoplasm **[FIG. 1C].** Quantitative real-time PCR (qRT-PCR) analysis revealed

that the transcript levels of *NORM* remain low during the G1 and S phases of the cell cycle.

However, there is a steady increase in transcript levels during the G2 phase, followed by a

subsequent decrease in the M phase **[FIG. 1D].** Cell cycle phase-specific expression of

lncRNAs is often associated with their role in that specific phase. An elevated level of *NORM*

in the G2 phase suggests its potential role in regulating G2/M progression. To understand

whether *NORM* is required for normal cell cycle progression and to examine the functional

relevance of *NORM*, Antisense oligonucleotide (ASO)- based depletion of *NORM* was

performed, followed by cell cycle analysis by using propidium iodide (PI) based fluorescence-

activated cell sorting (FACS), which showed a significant G2/M arrest in asynchronously

growing WI-38 cells **[FIG. 1E, F, and H]**. The effect of *NORM* depletion on cell cycle

progression was further confirmed by performing BrdU-PI flow cytometry. We observed a

significant increase in the G2/M population upon *NORM* depletion, confirming that *NORM*

depletion leads to cell cycle arrest at the G2/M phase **[FIG. G]**. It was evident from the cell

cycle analysis that the absence of *NORM* caused a significant G2/M arrest in the cell cycle,

indicating the importance of *NORM* in driving cells through the G2/M phase. We further

confirmed the role of *NORM* in driving G2/M progression by arresting the asynchronously

growing HeLa cells in mitosis with Nocodazole treatment, followed by subsequent release in

control and *NORM*-depleted conditions, and then analyzed by PI-FACS. PI-flow cytometry

analysis indicated that in the control condition, cells were correctly arrested upon nocodazole

treatment and subsequently progressed from the G2/M phase to the G1 phase upon release.

Nevertheless, in the *NORM* depletion condition, cells failed to progress from the G2/M phase

to the G1 phase even after 10 hours of release **[FIG. 1I & J].** Moreover, we observed that the

level of CDK1 was reduced upon *NORM* depletion compared to the control, as determined by

our immunoblot analysis **[Fig. 1K]**. This indicates the importance of *NORM* in driving the cells

through the G2/M phase. As DNA content-based cell cycle analysis is incapable of

distinguishing between the G2 and M-phase populations, we employed H3ser10
phosphorylation-based cell cycle analysis. A close examination of G2 and M phase
populations revealed that *NORM* depletion results in a substantial decrease in the mitotic
phase population and an increase in the G2 phase population, indicating a failure of the cells
to progress from the G2 to the M phase **[FIG. 1 L&M]**. This was further confirmed by
immunoblotting analysis, which checked the level of phospho-H3 at the ser10 residue. The
level of phospho-H3 (ser10) was significantly reduced upon *NORM* depletion **[FIG. 1 N]**.

Loss of *NORM* affects cellular proliferation, leading to an increase in apoptosis.

Depletion of *NORM* resulted in a marked increase in the G2/M population, prompting us to
investigate the effect of *NORM* on cellular proliferation. The effect on proliferation was
evaluated by performing Ki-67 immunostaining. The results showed a considerable decrease
in Ki-67-positive cell numbers in *NORM*-depleted conditions compared to control conditions
[FIG. 2A & B]. *NORM* depletion resulted in a substantial reduction in cellular viability and
proliferation, as well as a significant decrease in colony formation ability, as observed through
the MTT assay and clonogenic assay, respectively, confirming the observations about
proliferation **[FIG 2C, D, and E].** This data revealed that *NORM* depletion significantly reduced
cell proliferation, suggesting that *NORM* depletion can lead to defects in cell cycle progression.
The cell cycle analysis data showed an increase in the sub-G1 population upon *NORM*
depletion, indicating a significant level of apoptosis in the absence of the lncRNA. We then
determined the level of apoptosis in *NORM*-depleted cells by performing Annexin V-FITC and
propidium iodide (PI) based flow cytometry. The flow cytometry data showed an increase in
early and late apoptotic populations upon *NORM* depletion compared to those in control cells
[FIG. 2E & F]. Increased levels of cleaved PARP in *NORM*-depleted conditions further
validated the result. Additionally, anti-apoptotic protein Bcl2 levels were decreased, while pro-
apoptotic protein Bax levels were increased upon *NORM* depletion **[FIG. 2G].** The overall data
suggest the importance of *NORM* in promoting cellular proliferation and inhibiting apoptosis.

Loss of *NORM* results in changes in gene expression at the global transcriptomic and
proteomic levels.
To understand the molecular mechanism underlying the cell cycle defect upon *NORM*
depletion, we analyzed gene expression changes by performing a global transcriptome
analysis on control and *NORM*-depleted samples using the Illumina HiSeq 2500 platform.
Global transcriptome profiling revealed that the loss of *NORM* results in the differential
expression of 1,050 genes, wherein nearly 500 genes showed more than 2.5-fold up-
regulation, while 550 genes showed more than 2.5-fold down-regulation **[FIG. 3A]**. ZNF48,
SLC16A6, BRCA1, CHRND, PCNT, DCAKD, POT1, ZNF74, RNF14, and YY1AP1 were the

top down-regulated genes, while SEC31A, ITGA2, FBXO6, DNM2, SMURF1, GUCD1, WDR4,

POP1, PPP1R7, and PSMD1 were the top up-regulated genes **[Supplementary figure 1.1]**.

Using qRT-PCR, we validated the expression of several differentially expressed genes

(DEGs), which showed a similar trend **(Supplementary 1.2).** We next analysed the effect of

NORM on cellular biological pathways by performing gene ontology analysis. Gene ontology

revealed that many cell cycle-related biological processes and pathways were affected by

NORM depletion. The top ten down-regulated biological processes and upregulated biological

processes include cell cycle-related pathways such as regulation of mitotic cell cycle phase

transition, regulation of cell cycle phase transition, positive regulation of cell cycle, G2/M

transition of the mitotic cell cycle, and cell cycle G2/M phase transition **[FIG 3B &C]**. The

down-regulation of G2/M transition-related genes, such as MELK, CEP70, CDK2, PPP2R2A,

PCNT, and CDC25A, suggests a failure in the G2/M transition in the absence of *NORM*. To

gain further insight, we performed a proteomics analysis in *NORM*-depleted and control

conditions to check the effect of *NORM* depletion on different proteins and biological

processes. *NORM* depletion resulted in > 2-fold down-regulation of 146 proteins and > 2-fold

up-regulation of 679 proteins **[FIG 3D].** Many cell cycle-related proteins showed differential

expressions. Proteins known for their role in cell cycle regulation, such as TGM2, PSMD,

CLTC, PSMD2, BUB3, and ANXA4, were significantly upregulated. In contrast, proteins such

as PDGFRB, PTMS, COL1A1, CD2AP, LAMB2, YWHAB, CDK1, MCM3, and YWHAG were

significantly reduced upon *NORM* depletion **[Fig. 3E].** To further understand this, we

performed a Gene Ontology (GO) analysis of proteomics data using the DAVID tool. The gene

ontology analysis of the proteomics data revealed that biological processes, such as "negative

regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, anaphase-promoting

complex-dependent catabolic process, mitotic nuclear envelope disassembly, mitotic spindle

assembly, Cell cycle, and G2/M transition of the mitotic cell cycle," were affected **[Fig. 3F].**

The Gene Ontology data suggests that *NORM* is involved in regulating mitosis-related

pathways. Global transcriptome and proteomics profiling data indicate an overlap between

RNA-seq and proteomics profiles. Altogether, our high-throughput data suggests the

importance of *NORM* in regulating the cell cycle by associating with mitosis-related pathways.

***NORM* interacts with cell cycle regulatory proteins for chromosome segregation and**

cell cycle regulation

We next sought to investigate the mechanism of action of *NORM* in regulating the cell cycle.

We incubated the *in vitro* transcribed full-length biotinylated *NORM* with cell lysate, followed

by a pulldown of the *NORM*-protein complex using streptavidin beads **[FIG. 4A]**. *NORM*

showed interaction with numerous proteins, including cell cycle regulatory proteins CALM2,

CDC5L, SPOUT1, KHDRBS1, Nsun2, and   Plk1, out of which polo-like kinase 1 (Plk1)

seemed to be interesting, as Plk1 is required for entry of cells into mitosis. Our previous results

showed a defect in the G2/M transition under NORM depletion conditions [FIG. 4B & **C**]. The

NORM-Plk1 interaction was confirmed by performing RNA immunoprecipitation, which

showed significant enrichment (~3-fold) of *NORM* in the Plk1 immunoprecipitated **[FIG. 4D]**.

Interestingly, we also observed a marginal decline in Plk1 protein levels upon *NORM* depletion

[FIG. 4E]. Plk1 is one of the major kinases in mitosis, phosphorylating a multitude of substrates

at various subcellular locations to regulate mitotic events. Plk1 is essential for the proper

assembly of spindles, centrosome maturation, and the attachment of microtubules to

kinetochores. We then investigate the role of *NORM* on Plk1's localization at different

subcellular locations. We observed differential localization of Plk1 at various subcellular

locations, with some defects, in the *NORM*-depleted condition **[FIG. 4F].** To understand the

role of *NORM* on Plk1 localization at kinetochores and centrosomes, we examined the level

of Plk1 at kinetochores in control versus *NORM* depletion conditions using

immunofluorescence. We observed a significantly reduced intensity of Plk1 at kinetochores

upon *NORM* depletion compared to control cells, suggesting that *NORM* depletion affected

Plk1 localization at kinetochores **[FIG. 4 G&H].** We next sought to determine the effect of

NORM depletion on chromosome segregation. We observed that depletion of *NORM* leads to

defective chromosome segregation, marked by the misalignment of chromosomes during

mitosis, and a significantly higher number of cells showed lagging chromosomes at the spindle

pole **[Fig. 4 I & J]**.

***NORM* depletion hampered the interaction between   PLK1 and Bub1**

Next, to elucidate the mechanism of reduced localization of Plk1 at kinetochores, we examined

the effect of *NORM* depletion on the interaction of key regulatory proteins involved in mitosis.

With the help of string analysis, we found that many cell cycle regulatory proteins, such as

cyclin B, CENP-E, and Bub1, are known to interact with Plk1 **[FIG. 5A]**. The interaction

between Bub1 and Plk1 is crucial for the localization of Plk1 at kinetochores. Plk1 interacts

with Bub1 through its polo-box domain (PBD) and phosphorylates Bub1**.** First, we checked if

there was any effect of *NORM* depletion on the level of Bub1. We checked the kinetochore

localization of Bub1 in control and *NORM*-depleted cells. We observed a marginal change in

Bub1 intensity at the kinetochore upon *NORM* depletion **[FIG. 5B & C]**, and no significant

change was observed at the protein level of Bub1 upon *NORM* depletion **[FIG. 5D]**. We then

checked the effect of *NORM* on the interaction between Plk1 and Bub1. Interestingly, when

we immunoprecipitated Plk1, it was able to co-immunoprecipitate Bub1 along with it; however,

upon *NORM* depletion, the interaction between Plk1 and Bub1 was hampered, as Plk1 failed

to co-immunoprecipitate Bub1 **[FIG. 5E]**. The interaction was validated by performing reverse

Co-immunoprecipitation in which an antibody against Bub1 was used to immunoprecipitate

Bub1. Reverse Co-IP also showed that upon *NORM* depletion, the interaction between Plk1

and Bub1 was hampered **[FIG. 5F]**. It is known that CDK1 phosphorylates Bub1 at the T609

residue, and this phosphorylation is essential for the interaction between PLK1 and Bub1 (25)**.**

A mitosis-specific anti-MPM2 antibody can be used to detect Bub1 phosphorylated at the T609

residue, and phosphorylation of Bub1 at T609 is crucial for the Plk1-Bub1 interaction and the

localization of Plk1 at the kinetochore (26)**.** Considering the importance of Bub1 T609 in Plk1

interaction, we checked the effect of *NORM* depletion on Bub1 phosphorylation. We

immunoprecipitated Bub1 using an anti-Bub1 antibody and assessed the phosphorylation

status of Bub1 at T609 using an anti-MPM2 antibody. Interestingly, we observed that *NORM*

depletion led to a significant reduction in Bub1 phosphorylation at the T609 residue **[FIG. 5G**

& H], indicating that *NORM* is involved in mediating Bub1 phosphorylation. The depletion of

NORM resulted in a decrease in Bub1 phosphorylation, ultimately hindering Bub1's interaction

with Plk1**.** Altogether, these results suggest that the *NORM* is involved in mediating the

interaction between Plk1 and Bub1 through the phosphorylation of Bub1 at T609.

***NORM* mediates the binding of Nsun2 on CDK1 mRNA to stabilize CDK1 protein**

We investigated Bub1's upstream targets to gain a deeper mechanistic understanding of how

NORM regulates the phosphorylation of Bub1. It is known that Bub1 is phosphorylated at T609

by cyclin-dependent kinase 1 (CDK1). Therefore, we explore any potential association

between *NORM* and CDK1. Our RNA pulldown data showed that *NORM* lncRNA also interacts

with the tRNA methyltransferase Nsun2 (Misu). We validated this interaction by performing an

RNA pulldown followed by western blotting to verify the presence of Nsun2 **[Fig. 6A]**. Nsun2

binds to CDK1 mRNAs. It stabilizes them at the protein level by methylating them. Next, we

examined the effect of *NORM* depletion on Nsun2 at the protein level**.** We found no apparent

change in Nsun2 at the protein level, indicating that *NORM* does not directly control Nsun2

expression **[Fig. 6B].** Next, we examined the effect of *NORM* depletion on Nsun2 binding to

CDK1 mRNA with RNA-immunoprecipitation **[Fig. 6D]**. Interestingly, our RNA-IP with anti-

Nsun2 antibody showed that upon depletion of NORM, CDK1 enrichment on Nsun2 was

considerably lower than in control cells **[Fig. 6D].** These results suggested that *NORM*

depletion inhibits Nsun2's propensity to bind to CDK1 mRNA. Next, we checked the effect of

reduced binding on the CDK1 protein level. Immunoblotting data suggested that the CDK1

was reduced at the protein level upon NORM depletion [Fig. 6E], suggesting that the reduced

level of Nsun2 binding of CDK1 mRNA was hampered by *NORM* depletion, and hence it

resulted in reduced stability of CDK1 protein. This reduced level of CDK1 resulted in

decreased phosphorylation of Bub1 at T609, ultimately hindering the interaction between Plk1

and Bub1. Overall, the evidence suggests the necessity of *NORM* for chromosomal
segregation and normal cell cycle progression by mediating Nsun2's binding to CDK1 mRNA
and modulating the interaction between Bub1 and Plk1.

Discussion:

In this study, we have demonstrated that *NORM*, a long noncoding RNA, plays a crucial role
in regulating cell cycle progression from the G2 to M phase. We observed that *NORM* shows
an elevated level of expression in the G2 phase. Multiple studies have demonstrated that
lncRNAs exhibit tissue- and cell-stage-specific expression. This tissue- and cell-specific
expression is often associated with the function of lncRNAs in that cell or tissue. The
Kannanganattu V Prasanth group has demonstrated that more than 2,000 long noncoding
RNAs (lncRNAs) exhibit periodic expression during the cell cycle. (27). An elevated level of
lncRNA is found to be associated with cell stage-specific regulation of the cell cycle phases in
a cell stage-specific manner. Therefore, this periodic expression of *NORM* may play a crucial
role in regulating the cell cycle. Indeed, we found that when we depleted *NORM* cells, they
were arrested at the G2/M phase and were unable to move to the G1 phase upon release.
The arrest of cells may be due to the defective assembly of proteins required for mitotic
progression. Bida *et al.* also demonstrated that a mitosis-associated long noncoding RNA
(lncRNA), MA-linc1, is essential for mitosis. In the absence of lncRNA-MA, cells are unable to
progress from mitosis to the G1 phase of the cell cycle.

We evaluated the role of *NORM* in regulating cellular proliferation and found that *NORM* plays
a crucial part in this process, with depletion of *NORM* resulting in reduced cell proliferation.
The G2 phase is a critical phase for cell proliferation, as it determines the cell's fate, whether
it will progress into the M phase and divide into two daughter cells. Other evidence also
suggests that lncRNA depletion causes cell cycle arrest, leading to a decrease in cellular
proliferation.(28)**.** Reduced cellular proliferation was accompanied by an increase in the rate
of apoptosis and an increase in the level of DNA damage. When a cell is arrested at any
checkpoint for an extended period, the apoptotic cascade is activated**.** We also observed that
cells were arrested for a longer time in the G2/M phase. This arrest may have triggered the
apoptotic cascade, leading to an increased rate of apoptosis.

At the molecular level, a cell's entry into each phase is regulated by various types of cyclins,
cyclin-dependent kinases (CDKs), cyclin kinase inhibitors, and specific transcription factors.
We observe a significant change in the protein level of CDK1 upon *NORM* depletion. CDK1 is
a key regulator of the G2 and M phases of the cell cycle. It, along with cyclin A and Cyclin B,
regulates cell entry from the G2 phase to the M phase (29–32). A decrease in the level of

CDK1 is one possible reason cells are arrested at the G2/M boundary, and this defect also
causes defects in mitotic cells.

Through RNA sequencing analysis and proteomics analysis, we found that pathways such as
the Regulation of mitotic cell cycle phase transition and the G2/M transition of the mitotic cell
cycle were affected. This suggests that *NORM* plays a crucial role in cell cycle progression.
DE mRNAs, such as BRCA1, FBXO6, and PCNT, which are involved in cell cycle regulation,
were significantly affected. BRCA1 plays a crucial role in regulating the cell cycle(33,34).
PCNT is a significant protein that helps in assembling the PCM complex for centrosome
maturation(35–37). Therefore, alterations in various genes related to cell cycle progression
could have resulted in changes to biological processes associated with the cell cycle.
Proteomics analysis also demonstrated that many proteins and the pathways related to cell
proliferation and cell cycle were affected.

In this study, we observed a significant decrease in Plk1 localization at the kinetochore. At
kinetochore Plk1 interacts with Bub1, BubR1 and MAD2 proteins(38–41). The interaction of
Plk1 with these proteins is essential for the nucleation of PCM components, including PCNT
(36,42). The interaction of Plk1 at the kinetochore facilitates the attachment of the kinetochore
to the microtubules (MT). Lera et al. observed a similar result, showing that Plk1 inhibition can
cause chromosome missegregation, characterized by lagging chromosomes (43). Therefore,
the reduced Plk1 localization at the kinetochore may have impacted the target proteins CENP-
U, BubR1, PICH, CLIP-170, CLASP2, Survivin, USP16, and RSF1, for example, including
Sgt1 phosphorylation, which could result in improper attachment of microtubules to the
kinetochore.(44). PLK1 phosphorylates CENP-Q by binding to CENP-U, and the absence of
phosphorylation can lead to chromosome missegregation(45).

The interaction between Bub1 and Plk1 is crucial for the proper segregation of chromosomes
during cell division. In our study, we observed that *NORM* depletion hampers the interaction
between these two proteins. It has been reported in studies that Bub1 becomes
phosphorylated at its T609 residue by CDK1, a crucial event for the binding of Bub1 to the
PBD domain of Plk1. So, the reduced interaction between Bub1 and Plk1 is a consequence
of the reduced CDK1-mediated phosphorylation on Bub1 T609. Plk1 also interacts with CENP-
U, along with Bub1, at the kinetochore for chromosome segregation; however, this study has
not explored the effect of the interaction between CENP-U and Plk1. In our study, we observed
that in the absence of *NORM*, the binding of Nsun2 on CDK1 mRNA was significantly reduced.
Other studies have also demonstrated the importance of Nsun2 binding to CDK1 mRNA and
its significance in the translation of CDK1 mRNA by mediating methylation. Although our data
suggested a direct interaction between the Nsun2 protein and *NORM*, we did not observe a

direct interaction between NORM and CDK1 mRNA, indicating that *NORM* lncRNA and CDK1 mRNA do not form an RNA-RNA interaction complex. This suggests possibilities other than a direct RNA-RNA interaction. One of the limitations of our study is that we have not explored in detail how exactly the *NORM* mediates the interaction between Nsun2 and CDK1 mRNA, nor whether there is any change in the methylation of CDK1 mRNA. However, we speculate that *NORM* acts as a Guide lncRNA for Nsun2 protein to mediate the methylation of CDK1 mRNA, thereby increasing its translation and subsequently phosphorylating Bub1 at T609. Various studies have shown that lncRNAs can exert their functions by acting as a guide molecule for the protein (46).

MATERIALS AND METHODS:

Cell culture:

HeLa cells and Wi-38 cells were cultured in DMEM and MEM, respectively, supplemented with high glucose and 10% fetal bovine serum (FBS), as well as a penicillin-streptomycin antibiotics solution (Gibco). Cells were maintained at 37°C in a humidified atmosphere of 5% CO_2.

Antisense oligonucleotide treatment

Transient transfection of cells was performed using. For transfection, LNA GapmeRs Phosphorothioate internucleosidic linkage-modified antisense oligonucleotides were diluted in Opti-MEM. *NORM* Gapmers were used at a final concentration of 100 nM, twice (48 hours apart) within a 24-hour gap, to deplete Human *NORM*.

Flow cytometry:

PI-Flow cytometry was used to analyze the distribution of cell cycle phases. Cells were harvested using a scraper and then collected by centrifugation. Cells were washed with 1X PBS (phosphate-buffered saline) and fixed in ethanol for at least 4 to 5 hours or overnight at 4 °C. Cells were washed two times with 1XPBS and then incubated in 500ul of 1X PBS containing 0.1% Triton X-100, 20mg/ml propidium iodide, and 0.01mg/ml RNase A for 30 min at 37ºC. It was followed by cell cycle analysis using a FACSCalibur (BD Bioscience), and the data were analyzed using CellQuest Pro.

For BrdU-propidium iodide (PI), flow cytometry was performed as described earlier (Tripathi et al., 2013). Briefly, S-phase cells were labeled with BrdU at a final concentration of 50 µM and incubated for 1 hour at 37°C. Cells were further resuspended in chilled 0.9% NaCl and then fixed in an equal volume of ethanol, followed by incubation at −20°C for 1 hour. Furthermore, cells were resuspended and incubated in a 2N HCl + 0.5% Triton X-100 solution

452 for 30 minutes at room temperature, followed by washing in 0.1 M Sodium tetraborate solution.

453 Finally, the cells were resuspended in PBS/0.5% Tween-20 + 1% BSA and incubated with the

454 anti-BrdU antibody for 1 hour at RT. The cells were incubated in PBS + PI/Triton X-100 at

455 37°C for 15 min. Cells were analyzed using a FACScalibur flow cytometer (BD Bioscience),

456 and the data were analyzed with CellQuest Pro.

457 For mitotic cell counting, total cells were collected by trypsinization. It was followed by fixing

458 the cells in chilled 70% ethanol. Cells were permeabilized by using 0.25% Triton X-100. Cells

459 were incubated with H3ser10 antibody (Abcam, ab14955) for two hours at room temperature.

460 It was followed by brief washing and blocking of the cells with 1% BSA. Further, cells were

461 incubated with Alexa Fluor 488 secondary antibody for 30 minutes at room temperature.

462 Moreover, finally, cells were incubated with Propidium iodide (PI) containing RNase for 30

463 minutes. Cells were analyzed using a FACScalibur flow cytometer (BD Bioscience), and the

464 data were analyzed with CellQuest Pro.

465 To detect apoptosis, dual staining with Annexin V and propidium iodide (PI) was performed

466 according to the manufacturer's instructions (Invitrogen, cat. no R37174). Briefly, Wi-38 cells

467 were trypsinized, collected, and washed with ice-cold PBS. Cells were resuspended in 500 µL

468 of 1x binding buffer. A drop of Annexin-V FITC was added, and cells were incubated for 15

469 minutes at 25°C in the dark. 5 µL propidium iodide was added before acquiring the cells. Cells

470 were acquired using a BD FACScanto, and data were analyzed with CellQuest Pro.

471 **Total RNA extraction and quantitative real-time PCR (qRT-PCR):**

472 Total RNA was isolated from cells using Trizol reagent (Invitrogen) according to the

473 manufacturer's instructions, and the concentration was estimated using a UV

474 spectrophotometer. Genomic DNA was digested by DNase I (Sigma) treatment. Total RNA

475 was subjected to first-strand cDNA synthesis using Multiscribe Reverse Transcriptase and

476 Random Hexamers (Invitrogen). Transcript levels were quantified by quantitative real-time

477 PCR (qRT-PCR) using gene-specific primers.

478 **RNA-seq analysis:**

479 Whole-transcriptome analysis of control and *NORM*-depleted samples was performed on the

480 Illumina HiSeq 2500 platform to achieve high transcriptome coverage (50-100 million reads

481 per sample). Briefly, Total RNA was isolated by the RNeasy kit (Qiagen). RNA-seq libraries

482 were constructed using total RNA isolated from untreated and *NORM*-depleted samples with

483 the RNeasy kit (Qiagen). Samples were indexed with adaptors and submitted to paired-end

484 sequencing. RNA-seq reads were aligned with Tophat2.0.11 to the human genome. A

485 comparison of expression levels was calculated by using fragments per kilobase of transcripts

per million fragments mapped (FPKM). Gene ontology analysis was performed by using the

Database for Annotation, Visualization, and Integrated Discovery (DAVID) tool

(https://david.ncifcrf.gov).

Quantitative proteomics by label-free quantitation mass spectrometry

Human lung fibroblast primary cells (WI38) were seeded in 10 cm cell culture plates for both

the scrambled and NORM-depleted conditions. Cells were collected and pelleted in 1X PBS.

1X PBS was removed entirely, and the cell pellet was snap-frozen by liquid nitrogen for 20–

30 seconds and stored at -80 °C. Urea lysis buffer was used for cell lysis, and the cells were

sonicated to ensure complete lysis. Acetone precipitation was performed by incubating

overnight at -20 °C with acetone. Urea rehydration buffer was used for the elution of proteins,

followed by the removal of salts. An Amicon ultra-0.5 centrifugal filter unit with a 3 kDa cut-off

(UFC500394) was used to remove salt and concentrate the sample. Protein was estimated

using Pierce reagent, and bovine serum albumin (BSA) was used for plotting the standard

curve. An equal amount of protein (50 µg) was digested using the TFE-In solution digestion

protocol. Desalting and concentrating peptides or small proteins were performed using a

ZipTip with 0.6 µL C18 resin (ZTC18S096). Mass spectrometry sample preparation was

performed by adding 0.1% formic acid to dried protein samples. Samples were acquired by

injecting a 2 µL sample into the Thermo Scientific Orbitrap Fusion Tribrid LC-MS/MS system.

Raw files were transferred to the Proteome Discoverer software for analysis of the sample.

Cell proliferation assay:

Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide (MTT) assay. Briefly, after transfection with *NORM* ASO or scrambled oligos for 48

hours, HeLa cells were trypsinized, and a suspension of 5000 cells was seeded into a 96-well

plate. After 24 hours, 20 µL of MTT (5 mg/mL) was added, and the cells were incubated for

an additional 4 hours. Then, 150 µL of isopropanol was added to dissolve the crystals. The

proliferation ability of cells was assessed at 0 hours, 24 hours, 48 hours, 72 hours, and 96

hours by incubating the cells at 37°C. Absorbance at 570 nm was determined

spectrophotometrically by using a microplate reader. Colony-forming ability was checked by

the colony formation assay. Briefly, 1,000 cells were seeded in a six-well plate and maintained

for 2 weeks, during which the media were replaced every 3 days. Colonies were fixed by PFA

and stained by using crystal violet in PBS for 30 minutes. The colony formation ability was

assessed by counting stained colonies.

Immunoblotting

Cells were washed twice with PBS and then collected by scraping. A lysis buffer containing protease and phosphatase inhibitor was used for extraction. Loading dye was added directly to the samples, and the samples were denatured by boiling for 5 min at 95°C. The total cell lysate was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and proteins were transferred to the PVDF membrane. The membrane was incubated with primary antibodies overnight at 4°C. An appropriate secondary antibody was incubated for 1 hour at room temperature. The antibodies used for immunoblotting were anti-CDK1(Cdc2) (1:1000; Santa Cruz SC-54), anti-PARP (1:1000; Cell signaling technology, 9542), anti-Bax (1:500; Santa Cruz sc493), anti-Bcl2 (1:500; Santa Cruz sc492), anti-Plk1 (1:1000 Abcam ab17056), anti-Cyclin A (1:1000; Santa Cruz sc271682), anti-Cyclin B(1:1000; Santa Cruz sc7393), anti-Cyclin E (1:1000; Santa Cruz sc377100), anti-CDK4(1:1000; Santa Cruz sc23896), anti-Bub1(1:100 ab54893), H3ser10 antibody (1:1000; ab14955;), anti-α-Tubulin (1:5000; Sigma T6199), Anti-mouse IgG, HRP-linked (1:5000; cell signalling technology; 7076), Anti-rabbit IgG, HRP-linked (1:5000; cell signalling technology; 7074).

Immunostaining:

Immunofluorescence was performed as described earlier (Tripathi et al., 2013). Briefly, Wi-38 cells, grown on coverslips, were then fixed in 2% PFA for 20 minutes at room temperature (RT) and permeabilized with 0.1% Triton X-100 for 10 minutes on ice. Cells were blocked by incubating with 5% fetal bovine serum (FBS) at room temperature (RT) for 1 hour, followed by incubation with the primary antibody for 2 hours at RT. Incubation with fluorescence-tagged secondary antibody was performed for 1 hour at room temperature. Finally, cells were stained with Hoechst and mounted in mounting media. The antibodies were used are Ki-67 (1:500; Abcam; ab16667), anti-Plk1 (1:100 Abcam; ab17056), anti-α-Tubulin (1:1000; Sigma T6199), anti-Bub1(1:100; Abcam; ab195268), anti-Pericentrin (1:200; Novus; NB 100-61071) CREST (1:500; antibodiesinc; 115-234), Alexa flour 488 donkey anti-rabbit IgG (H+L) (1:1000; Invitrogen; A21206), Alexa flour 594 donkey anti-mouse IgG (H+L) (1:1000; Invitrogen; A21203) images were acquired on Zeiss microscope.

RNA pulldown and Mass spectrometry analysis:

NORM was cloned into a pGEMT vector. The plasmid was linearized by using the NcoI restriction enzyme. Purified plasmids were then used for in vitro transcription with a Biotin RNA labeling Mix (Roche). Biotin labeling was done by using T7 polymerase at 37°C for 6 hours. In vitro transcribed RNA was then purified by passing it through a MicroSpin column (Illustra MicroSpin G-25 columns, 27-5325-01, Merck). Fresh lysate was prepared by using Protein extraction buffer (20 mM Tris HCl, pH 7.5, 100 mM KCl,5 mM MgCl2,0.5% NP40) with

protease, phosphatase cocktail inhibitors, and RNase inhibitors. The lysate was precleared using magnetic streptavidin Dynabeads (M-280 streptavidin, Cat. No. 11205D, Invitrogen). Biotin-labeled RNA and lysate were incubated on a rotator for 2 hours. It was followed by the addition of magnetic streptavidin Dynabeads to a mixture of RNA-lysate. It was further incubated for 2 hours. Next, protein samples were separated by SDS-PAGE, and bands were visualized by silver staining. For mass spectrometry analysis, the immunoprecipitated protein was washed with 100 mM ammonium bicarbonate. Proteins were prepared for mass spectrometry by digesting with RapiGest at 60°C for 30 minutes and then analysed by mass spectrometry.

RNA Immunoprecipitation:

Cells were washed twice with ice-cold phosphate-buffered saline (PBS). Cells were irradiated with $300mJ/cm^2$ in a UV crosslinker. The cell lysate was prepared by using RSB100 lysis buffer (100 mM Tris-Cl, pH 7.4, 100 mM NaCl, 2.5 mM $MgCl_2$, 0.5% NP40, 0.5% Triton X-100) by incubating on ice for 15 minutes. The lysate was centrifuged, and the supernatant was collected. 0.1M DTT, RNase Inhibitor, and DNase I were added to the supernatant. The lysate was precleared by incubating Protein G agarose beads (Pierce, Cat. No. 20398) at 4°C for 1 hour, rotating on a rotor shaker. Immunoprecipitation was performed by incubating an equal amount of lysate with an anti-Plk1 antibody (1:100; Abcam, ab17056), an anti-Nsun2 (1:100; Abcam, ab259941), and a mouse IgG antibody (Negative control) overnight on a rotator shaker at 4 °C. Next, protein G agarose beads were added and incubated further for 2 hours. Co-immunoprecipitated RNA was isolated by resuspending the beads in 1 mL of Trizol (Invitrogen). RNA was isolated according to the manufacturer's instructions. cDNA was prepared using 5X PrimeScript RT Master Mix (Takara, cat. no RR036A-1).

References:

1.   Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999;287(5):821–8.

2.   Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220–7.

3.   Holland AJ, Cleveland DW. Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep [Internet]. 2012;13(6):501–14. Available from: http://dx.doi.org/10.1038/embor.2012.55

4.   Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: From epigenetics to mitotic checkpoint signaling. Cell. 2003;112(4):407–21.

588 5. Lara-gonzalez P, Pines J, Desai A. Spindle assembly checkpoint activation and
589   silencing at kinetochores. Semin Cell Dev Biol [Internet]. 2021;117:86–98. Available
590   from: https://doi.org/10.1016/j.semcdb.2021.06.009

591 6. Lara-gonzalez P, Westhorpe FG. The Spindle Assembly Checkpoint. Curr Biol
592   [Internet]. 2012;22(22):R966–80. Available from:
593   http://dx.doi.org/10.1016/j.cub.2012.10.006

594 7. Overlack K, Primorac I, Vleugel M, Krenn V, Maffini S, Hoffmann I, et al. A molecular
595   basis for the differential roles of Bubl and BubR1 in the spindle assembly checkpoint.
596   Elife. 2015;2015(4):1–24.

597 8. Yamagishi Y, Yang CH, Tanno Y, Watanabe Y. MPS1/Mph1 phosphorylates the
598   kinetochore protein KNL1/Spc7 to recruit SAC components. Nat Cell Biol.
599   2012;14(7):746–52.

600 9. Singh P, Pesenti ME, Maffini S, Srinivasamani A, Singh P, Pesenti ME, et al. BUB1
601   and CENP-U , Primed by CDK1 , Are the Main PLK1 Kinetochore Receptors in
602   Mitosis ll BUB1 and CENP-U Primed by CDK1 , Are the Main PLK1 Kinetochore
603   Receptors in Mitosis. Mol Cell [Internet]. 2021;81(1):67-87.e9. Available from:
604   https://doi.org/10.1016/j.molcel.2020.10.040

605 10. Josue E, Nebreda AR, Fernandez M. A Two-Step Inactivation Mechanism of Myt1
606   Ensures CDK1 / Cyclin B Activation and Meiosis I Entry. Curr Biol. 2010;717–23.

607 11. Malumbres M. Cyclin-dependent kinases. Malumbres Genome Biol. 2014;1–10.

608 12. Xing J, Yi J, Cai X, Tang H, Liu Z, Zhang X, et al. NSun2 Promotes Cell Growth via
609   Elevating Cyclin-Dependent Kinase 1 Translation. Mol Cell Biol. 2015;35(23):4043–
610   52.

611 13. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al. Long Noncoding
612   RNA MALAT1 Controls Cell Cycle Progression by Regulating the Expression of
613   Oncogenic Transcription Factor B-MYB. PLoS Genet. 2013;9(3).

614 14. Wang C, Yang Y, Zhang G, Li J, Wu X, Ma X, et al. Long noncoding RNA EMS
615   connects c-Myc to cell cycle control and tumorigenesis. PNAS. 2019;

616 15. Su C, Wang W, Mo J, Liu F, Zhang H, Liu Y, et al. Long noncoding RNA HOXC - AS3
617   interacts with CDK2 to promote proliferation in hepatocellular carcinoma. Biomark Res
618   [Internet]. 2022;1–15. Available from: https://doi.org/10.1186/s40364-022-00411-2

619 16. Chen W, Zhou Z, Ren Y, Zhang L, Sun L, Man Y, et al. Effects of long non-coding

620  RNA LINC00667 on renal tubular epithelial cell proliferation , apoptosis and renal fi
621  brosis via the miR-19b-3p / LINC00667 / CTGF signaling pathway in chronic renal
622  failure. Cell Signal [Internet]. 2019;54(October 2018):102–14. Available from:
623  https://doi.org/10.1016/j.cellsig.2018.10.016

624 17. Yang H, Yang W, Dai W, Ma Y, Zhang G. LINC00667 promotes the proliferation ,
625  migration , and pathological angiogenesis in non – small cell lung cancer through
626  stabilizing VEGFA by EIF4A3. cell Biol Int [Internet]. 2020;(April):1671–80. Available
627  from: https://doi.org/10.1002/cbin.11361

628 18. Pei Liu, Shuofan Chen, Yangyue Huang, Shuai Xu, Hongcheng Song WZ and NS.
629  LINC00667 promotes Wilms tumor metastasis and stemness by sponging miR-200b
630  c.pdf. cell Biol Int. 2020;

631 19. Ren S, Zhang Y, Yang X, Li X, Zheng Y, Liu Y. N6-methyladenine- induced
632  LINC00667 promoted breast cancer progression through m6A / KIAA1429 positive
633  feedback loop. Bioengineered [Internet]. 2022;13(5):13462–73. Available from:
634  https://doi.org/10.1080/21655979.2022.2077893

635 20. Zhao J, Chen P, Tan C, Cheng X, Zhang W, Shen C. LncRNA LINC00667 gets
636  involved in clear cell renal cell carcinoma development and chemoresistance by
637  regulating the miR-143- 3p / ZEB1 axis. Aging (Albany NY). 2023;15(19):10055–71.

638 21. Li J, Kang J, Liu W, Liu J, Pan G, Mao A, et al. Docetaxel-resistant triple-negative
639  breast cancer cell-derived exosomal lncRNA LINC00667 reduces the
640  chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2
641  axis. Eur J Histochem. 2022;66.

642 22. Liao B, Yi Y, Zeng L, Wang Z, Zhu X, Liu J, et al. LINC00667 Sponges miR-4319 to
643  Promote the Development of Nasopharyngeal Carcinoma by Increasing FOXQ1
644  Expression. Front Oncol. 2021;10(January):1–10.

645 23. Pan J, Zang Y. LINC00667 Promotes Progression of Esophageal Cancer Cells by
646  Regulating miR - 200b - 3p / SLC2A3 Axis. Dig Dis Sci [Internet]. 2022;67(7):2936–
647  47. Available from: https://doi.org/10.1007/s10620-021-07145-5

648 24. Li J, Guan C, Hu Z, Liu L, Su Z, Kang P, et al. Yin Yang 1 - induced LINC00667 up -
649  regulates pyruvate dehydrogenase kinase 1 to promote proliferation , migration and
650  invasion of cholangiocarcinoma cells by sponging miR - 200c - 3p. Hum Cell
651  [Internet]. 2021;34(1):187–200. Available from: https://doi.org/10.1007/s13577-020-
652  00448-1

25.   Singh P, Pesenti ME, Maffini S, Carmignani S, Hedtfeld M, Petrovic A, et al. BUB1
and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis.
Mol Cell [Internet]. 2021;81(1):67-87.e9. Available from:
https://doi.org/10.1016/j.molcel.2020.10.040

26.   Qi W, Tang Z, Yu H. Phosphorylation- and Polo-Box – dependent Binding of Plk1 to
Bub1 Is Required for the Kinetochore Localization of Plk1. Mol Biol Cell.
2006;17(August):3705–16.

27.   Hao Q, Zong X, Sun Q, Lin Y, Song YJ, Hashemikhabir S, et al. The S-phase-induced
lncRNA SUNO1 promotes cell proliferation by controlling YAP1 / Hippo signaling
pathway. Elife. 2020;1–33.

28.   Zhang X, Wu N, Wang J, Li Z. LncRNA MEG3 inhibits cell proliferation and induces
apoptosis in laryngeal cancer via miR-23a/APAF-1 axis. J Cell Mol Med.
2019;23(10):6708–19.

29.   Ubersax JA, Woodbury EL, Quang PN. Targets of the cyclin-dependent kinase Cdk1.
Nature. 2003;859–64.

30.   Porter LA, Donoghue DJ. Cyclin B1 and CDK1 : Nuclear localization and upstream
regulators Cyclin B1 and CDK1 : nuclear localization and upstream regulators. Prog
Cell Cycle Res. 2003;(February).

31.   Gavet O, Pines J. Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to
Mitosis. Dev Cell [Internet]. 2010;18(4):533–43. Available from:
http://dx.doi.org/10.1016/j.devcel.2010.02.013

32.   Cerqueira A, Hunt S, Tardy C, Newton K, Santamarı D, Dubus P, et al. Cdk1 is
sufficient to drive the mammalian cell cycle. Nature. 2007;448(August):811–6.

33.   Deng CX. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response
and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–26.

34.   Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-Phase and G2-Phase
Checkpoints after Ionizing Irradiation. Mol Cell Biol. 2001;21(10):3445–50.

35.   Kim J, Kim J, Rhee K. PCNT is critical for the association and conversion of centrioles
to centrosomes during mitosis. J Cell Sci. 2019;132(6).

36.   Kim J, Lee K, Rhee K. PLK1 regulation of PCNT cleavage ensures fidelity of centriole
separation during mitotic exit. Nat Commun. 2015;

37.   Tibelius A, Marhold J, Zentgraf H, Heilig CE, Neitzel H, Ducommun B, et al.

Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1.
J Cell Biol. 2009;185(7):1149–57.

38.   Schmucker S, Sumara I. Molecular dynamics of PLK1 during mitosis. Mol Cell Oncol.
2014;(June):1–9.

39.   Lee K, Rhee K. PLK1 phosphorylation of pericentrin initiates centrosome maturation
at the onset of mitosis. J Cell Biol. 2011;195(7):1093–101.

40.   Gheghiani L, Loew D, Gavet O. PLK1 Activation in Late G2 Sets Up Commitment to
Mitosis. Cell Rep. 2017;2060–73.

41.   Ikeda M, Tanaka K. Plk1 bound to Bub1 contributes to spindle assembly checkpoint
activity during mitosis. Sci Rep [Internet]. 2017;(September 2016):1–15. Available
from: http://dx.doi.org/10.1038/s41598-017-09114-3

42.   Lee K, Rhee K. PLK1 phosphorylation of pericentrin initiates centrosome maturation
at the onset of mitosis. J Cell Sci. 2011;195(7):1093–101.

43.   Lera RF, Norman RX, Dumont M, Dennee A, Martin-koob J, Fachinetti D, et al. Plk 1
protects kinetochore – centromere architecture against microtubule pulling forces.
EMBO Rep. 2019;1–16.

44.   Liu XS, Song B, Tang J, Liu W, Kuang S, Liu X. Plk1 Phosphorylates Sgt1 at the
Kinetochores To Promote Timely. 2012;32(19):4053–67.

45.   Kang YH, Park C, Kim T, Soung N, Bang JK, Kim BY, et al. Mammalian Polo-like
Kinase 1-dependent Regulation of the PBIP1-CENP-Q Complex at Kinetochores * □.
J Biol Chem [Internet]. 2011;286(22):19744–57. Available from:
http://dx.doi.org/10.1074/jbc.M111.224105

46.   Zhao Z, Sentürk N, Song C, Grummt I. lncRNA PAPAS tethered to the rDNA
enhancer recruits hypophosphorylated CHD4 / NuRD to repress rRNA synthesis at
elevated temperatures. GENES Dev. 2018;836–48.

A]

SCR   NORM ASO

-2.00
-1.33
-0.67
0.00
0.67
1.33
2.00

B]

Downregulated_BP

- regulation of mitotic cell cycle phase transition
- regulation of cell cycle phase transition
- positive regulation of cell cycle
- intracellular receptor signaling pathway
- regulation of small GTPase mediated signal transduction
- G2/M transition of mitotic cell cycle
- cell cycle G2/M phase transition
- regulation of G2/M transition of mitotic cell cycle
- regulation of cell cycle G2/M phase transition
- positive regulation of mitotic cell cycle
- protein autoubiquitination
- protein K48-linked ubiquitination
- melanosome organization
- pigment granule organization
- regulation of defense response to virus by virus

GeneRatio

Count: 5, 10, 15, 20, 25

p.adjust: 2e-04, 4e-04, 6e-04

C]

Upregulated_BP

- response to virus
- protein modification by small protein removal
- defense response to virus
- protein deubiquitination
- regulation of animal organ morphogenesis
- regulation of protein ubiquitination
- morphogenesis of a polarized epithelium
- negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
- negative regulation of cysteine-type endopeptidase activity
- positive regulation of protein ubiquitination
- regulation of ERBB signaling pathway
- cell-substrate junction assembly
- response to type I interferon
- protein K63-linked deubiquitination
- mammary gland epithelial cell proliferation

GeneRatio

Count: 5, 10, 15, 20

p.adjust: 1e-04, 2e-04, 3e-04, 4e-04, 5e-04

D]

NORM ASO   SCR
I   II   III   I   II   III

Class
NORM ASO
SCR

2, 1, 0, -1, -2

E]

Upregulated		Downregulated	
Gene	Fold change	Protein	Fold change
TGM2	18.648	PDGFRB	0.016
PSMD1	18.52	PTMS	0.025
CLTC	15.713	COL1A1	0.096
PSMD2	14.44	CD2AP	0.131
PSMA4	12.72	LAMB2	0.133
ANXA4	12.352	YWHAB	0.191
BUB3	11.486	COL1A2	0.242
BANF1	11.348	CDK1	0.263
RCC1	10.743	RAD21	0.285
DDB1	9.771	PPP2R5D	0.296
PRKDC	9.565	MCM3	0.382
DYNC1H1	9.426	RBX1	0.397
CTTN	9.028	YWHAG	0.422
NUP50	6.697	SMC4	0.435
SBDS	6.387	CCDC124	0.436
PSMB1	6.372	YWHAE	0.438
GNAI2	6.25	MCM5	0.48
HMGA2	6.021		

F]

Downregulated		Upregulated	
Pathway	Count	Pathway	Count
negative regulation of apoptotic process	26	PI3K-Akt signaling pathway	9
cell proliferation	22	cell division	8
negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle	17	Cell cycle	8
positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition	17	cell migration	5
anaphase-promoting complex-dependent catabolic process	17	G2/M transition of mitotic cell cycle	4
DNA damage response, detection of DNA damage	7	regulation of actin cytoskeleton organization	3
mitotic nuclear envelope disassembly	6	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	3
mitotic spindle organization	5	positive regulation of DNA biosynthetic process	2
mitotic spindle assembly	5		

B]

Gene	Sum PEP score
XRN2	5.424
FUS	3.806
GNL3	9.488
KHDRBS1	5.627
NSUN2	3.706
ARHGEF2	1.483
SPOUT1	1.524
XRCC6	5.008
CALM2	7.023
CDC5L	3.339
GAPDH	2.324
MRPS26	3.483
PLK1	1.833
RPS27A	2.352
RPS6	8.711
TUBA1B	18.025
TUBB	20.338